Editorial Material
Cell Biology
Li Xin
Summary: EZH2 has been shown to promote the development of castration-resistant prostate cancer (CRPC) by interacting with the androgen receptor (AR) to reprogram its transcriptional activity, facilitating the transition of CRPC into a lineage infidelity state.
NATURE CELL BIOLOGY
(2021)
Article
Oncology
Jun Hao, Xinpei Ci, Yong Wang, Stephen Yiu Chuen Choi, Sarah E. Sullivan, Hui Xue, Rebecca Wu, Xin Dong, Anne M. Haegert, Colin C. Collins, Dong Lin, Yuzhuo Wang
Summary: The study revealed a reciprocal feedback between GRB10 and AR signaling, indicating the importance of GRB10 in the progression of prostate cancer.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
Qianyu Guo, Margarita Bartish, Christophe Goncalves, Fan Huang, Julian Smith-Voudouris, Sai Sakktee Krisna, Samuel E. J. Preston, Audrey Emond, Vivian Z. Li, Claudia U. Duerr, Yirui Gui, Aurelie Cleret-Buhot, Pamela Thebault, Hanne Lefrere, Liesbeth Lenaerts, Dany Plourde, Jie Su, Barbara C. Mindt, Shannon A. Hewgill, Tiziana Cotechini, Charles C. T. Hindmarch, William Yang, Elie Khoury, Yao Zhan, Valeria Narykina, Yuhong Wei, Giuseppe Floris, Mark Basik, Frederic Amant, Daniela F. Quail, Rejean Lapointe, Jorg H. Fritz, Sonia del Rincon, Wilson H. Miller
Summary: In postpartum breast cancer (PPBC), inhibition of the MNK1/2-eIF4E axis can reduce lung metastasis and impact the tumor and lung immune microenvironment; the repression of IL33 production and enhancing the efficacy of anti-PD-1 immunotherapy by blocking phospho-eIF4E are potential therapeutic approaches.
Article
Oncology
Sathyen A. Prabhu, Omar Moussa, Christophe Goncalves, Judith H. LaPierre, Hsiang Chou, Fan Huang, Vincent R. Richard, Pault Y. M. Ferruzo, Elizabeth M. Guettler, Isabel Soria-Bretones, Laura Kirby, Natascha Gagnon, Jie Su, Jennifer Silvester, Sai Sakktee Krisna, April A. N. Rose, Karen E. Sheppard, David W. Cescon, Frederick A. Mallette, Rene P. Zahedi, Christoph H. Borchers, Sonia V. del Rincon, Wilson H. Miller Jr
Summary: This article investigates the use of CDK4/6 inhibitor palbociclib in melanoma and finds that the treatment induces phosphorylation of eIF4E, leading to increased translation of proteins involved in cell survival and evasion of the drug's antitumor effects.
MOLECULAR CANCER THERAPEUTICS
(2023)
Article
Chemistry, Multidisciplinary
Zhuangzhuang Zhang, Lijun Cheng, Qiongsi Zhang, Yifan Kong, Daheng He, Kunyu Li, Matthew Rea, Jianling Wang, Ruixin Wang, Jinghui Liu, Zhiguo Li, Chongli Yuan, Enze Liu, Yvonne N. Fondufe-Mittendorf, Lang Li, Chi Wang, Xiaoqi Liu, Tao Han
Summary: The study introduces a novel network-based systems biology approach, XDeath, to identify crosstalk of signaling pathways associated with PCa progression, and reveals the important roles of Plk1 and DNMT3a-related signaling pathways in PCa advancement, with a negative feedback mechanism between the two proteins.
Article
Medicine, Research & Experimental
Sujata Jana, Rucha Deo, Rowan P. Hough, Yuzhen Liu, Jessie L. Horn, Jonathan L. Wright, Hung-Ming Lam, Kevin R. Webster, Gary G. Chiang, Nahum Sonenberg, Andrew C. Hsieh
Summary: This study showed that protein synthesis is essential for urothelial cancer formation and growth but not necessary for bladder homeostasis. Phosphorylation of eIF4E at serine 209 plays a critical role in bladder cancer initiation and progression, with tumors having high levels of eIF4E phosphorylation showing sensitivity to specific inhibitors.
Article
Medicine, Research & Experimental
C. Pinto-Diez, R. Ferreras-Martin, R. Carrion-Marchante, J. Klett-Mingo, M. Garcia-Hernandez, M. Perez-Morgado, S. Sacristan, M. Barragan, M. Seijo-Vila, I Tundidor, S. Blasco-Benito, E. Perez-Gomez, I Gomez-Pinto, C. Sanchez, C. Gonzalez, V. M. Gonzalez, M. E. Martin
Summary: Breast cancer is the most common and deadly cancer for women worldwide. In this study, a specific aptamer called apMNKQ2 was optimized and shown to inhibit the proliferation, colony formation, migration, and invasion of breast cancer cells. It also demonstrated efficacy in reducing tumor volume and metastasis in mouse models.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2022)
Article
Oncology
Juliana Felgueiras, Joao Lobo, Vania Camilo, Isa Carneiro, Barbara Matos, Rui Henrique, Carmen Jeronimo, Margarida Fardilha
Summary: This study analyzed the expression, localization, and regulation of PP1c isoforms in prostate cancer (PCa), finding that PP-1A was upregulated and relocalized towards the nucleus in PCa, while PPP1CA was frequently amplified in advanced stages. PP-1B was downregulated but upregulated in a subset of tumors with AR amplification. PP1c-coding genes were rarely mutated in PCa and not prone to regulation by promoter methylation. Protein phosphorylation might play an important role in regulating the activity of PP1c isoforms.
EXPERIMENTAL CELL RESEARCH
(2022)
Article
Cell Biology
Shimiao Zhu, Zhao Yang, Zheng Zhang, Hongli Zhang, Songyang Li, Tao Wu, Xuanrong Chen, Jianing Guo, Aixiang Wang, Hao Tian, Jianpeng Yu, Changwen Zhang, Lei Su, Zhiqun Shang, Changyi Quan, Yuanjie Niu
Summary: Resistance to antiandrogen is lethal for castration-resistant prostate cancer (CRPC). In this study, we identified HOXB3 as an independent risk factor for progression and death in metastatic CRPC. We demonstrated that HOXB3 activation was associated with WNT pathway genes expression, and suppression of HOXB3 sensitized CRPC to abiraterone treatment. Our findings suggest that targeting HOXB3 may benefit a subgroup of CRPC resistant to antiandrogen therapy.
CELL DEATH & DISEASE
(2023)
Review
Biochemistry & Molecular Biology
Ivana Samarzija
Summary: The specific functional form of a protein is mostly achieved through dynamic interactions of many enzymes in post-translational modifications, which cells widely use to respond to stimuli, regulate transcription, and maintain proteostasis. Post-translational modifications play important roles in driving prostate cancer, particularly in regulating protein activity at the level of post-translational modifications.
Article
Biochemistry & Molecular Biology
Yu-Chen Lee, Song-Chang Lin, Guoyu Yu, Ming Zhu, Jian H. Song, Keith Rivera, Darryl Pappin, Christopher J. Logothetis, Theocharis Panaretakis, Guocan Wang, Li-Yuan Yu-Lee, Sue-Hwa Lin
Summary: The study reveals that tumor-induced endothelial cells transitioning into osteoblasts lead to bone formation, enhancing the metastatic potential of prostate cancer cells. Tenascin C (TNC) is identified as a major protein secreted during this process, promoting prostate cancer cell migration through various signaling pathways. Targeting TNC may hold promise for prostate cancer therapy.
Article
Cell Biology
Alastair Davies, Shaghayegh Nouruzi, Dwaipayan Ganguli, Takeshi Namekawa, Daksh Thaper, Simon Linder, Fatih Karaoglanoglu, Meltem E. Omur, Soojin Kim, Maxim Kobelev, Sahil Kumar, Olena Sivak, Chiara Bostock, Jennifer Bishop, Marlous Hoogstraat, Amina Talal, Suzan Stelloo, Henk van der Poel, Andries M. Bergman, Musaddeque Ahmed, Ladan Fazli, Haojie Huang, Wayne Tilley, David Goodrich, Felix Y. Feng, Martin Gleave, Housheng Hansen He, Faraz Hach, Wilbert Zwart, Himisha Beltran, Luke Selth, Amina Zoubeidi
Summary: The study demonstrates that prostate cancer can transition to a high-plasticity state in response to potent androgen receptor antagonism, maintaining AR activity and rerouting transcriptional activity through changes in chromatin architecture. This reprogramming is mediated by EZH2 and favors stem cell and neuronal gene networks, highlighting the potential for reversing treatment resistance in prostate cancer.
NATURE CELL BIOLOGY
(2021)
Article
Oncology
Duy T. Nguyen, Wei Yang, Arun Renganathan, Cody Weimholt, Duminduni H. Angappulige, Thanh Nguyen, Robert W. Sprung, Gerald L. Andriole, Eric H. Kim, Nupam P. Mahajan, Kiran Mahajan
Summary: This study reveals that HOXB13 exacerbates the antagonism of androgen receptor (AR) in castration-resistant prostate cancers (CRPC), and identifies a novel lysine 13 (K13) acetylation in HOXB13. Acetylated K13-HOXB13 serves as a clinical biomarker for the development of CRPC and promotes the expression of lineage, diagnostic, CRPC-promoting, and angiogenesis genes. The HOXB13 target ACK1 could be a potential therapeutic target for inhibiting CRPC growth.
CLINICAL CANCER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Wanting Han, Mingyu Liu, Dong Han, Muqing Li, Anthia A. Toure, Zifeng Wang, Anna Besschetnova, Susan Patalano, Jill A. Macoska, Shuai Gao, Housheng Hansen He, Changmeng Cai
Summary: The genomic loss of RB1 is a common alteration in CRPC and is associated with poor patient outcomes. RB1 loss is also crucial for the neuroendocrine transdifferentiation of PCa induced by ARSi. Through cistromic and transcriptomic analysis, it has been found that RB1 has distinct binding sites and targets in CRPC with different genomic backgrounds. Furthermore, it has been discovered that the activity of E2F1 in Rb-deficient CRPC is highly dependent on LSD1/KDM1A, and that Rb inactivation sensitizes CRPC tumors to LSD1 inhibitor treatment.
Article
Multidisciplinary Sciences
Simon Uzor, Sean R. Porazinski, Ling Li, Bethany Clark, Masahiko Ajiro, Kei Iida, Masatoshi Hagiwara, Abdullah A. Alqasem, Claire M. Perks, Ian D. Wilson, Sebastian Oltean, Michael R. Ladomery
Summary: Dysregulation of alternative splicing is a feature of cancer, and targeting CDC2-like kinases may provide new therapeutic opportunities in prostate cancer.
SCIENTIFIC REPORTS
(2021)